更新于：2024-12-24
Deutetrabenazine
氘丁苯那嗪
更新于：2024-12-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2017-04-03), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、优先审评 (中国)、孤儿药 (韩国)、临床急需境外新药 (中国)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C19H27NO3 |
InChIKeyMKJIEFSOBYUXJB-QBUQIWBYSA-N |
CAS号1392826-25-3 |
关联
19
项与 氘丁苯那嗪 相关的临床试验一项评价单次给药12 mg安泰坦®片剂在健康中国受试者中的氘丁苯那嗪及其活性代谢物的药代动力学特征的开放性、单剂量研究
An Open-label, Single Dose Trial to Characterize the Pharmacokinetics of Deutetrabenazine and its Active Metabolites in Healthy Chinese Participants After a Single Dose of a 12-mg AUSTEDO® Tablet
随机、开放、两制剂、两序列、四周期、完全重复交叉设计评估中国健康受试者空腹/餐后状态下口服氘丁苯那嗪片的人体生物等效性试验
100 项与 氘丁苯那嗪 相关的临床结果
登录后查看更多信息
100 项与 氘丁苯那嗪 相关的转化医学
登录后查看更多信息
100 项与 氘丁苯那嗪 相关的专利（医药）
登录后查看更多信息
64
项与 氘丁苯那嗪 相关的文献（医药）2023-11-01Current medicinal chemistry
Clinical Application and Synthesis Methods of Deuterated Drugs
Article
作者: Rao, Guo-Wu ; Zhang, Wen ; Xu, Xiao-Liang
Abstract::
Many drugs have adverse absorption, distribution, metabolism, and excretory
(ADME) properties that prevent their widespread use or limit their use in some indications.
In addition to preparation techniques and prodrug strategies, deuterium modification
is a viable method for improving ADME properties. Deuterated drugs have attracted
increasing attention from the pharmaceutical industry in recent years. To date, two deuterated
drugs have been approved by the FDA. In 2017, austedo was approved by the FDA
as a new drug for Huntington's disease in the United States, the first deuterium drug to be
marketed worldwide. Recently (June 9, 2021), donafinil has been listed in China; this result
has caused major pharmaceutical companies and the pharmaceutical industry to pay
attention to deuterium technology again. In addition, BMS-986165, RT001, ALK-001,
HC-1119, AVP-786 and other drugs are in phase III clinical studies, and some solid deuterium
compounds have entered phase I and II clinical trials. The deuterium strategy has
been widely used in pharmaceutical research and has become a hot spot in pharmaceutical
research in recent years. In this paper, the research and development of deuterated
drugs are reviewed, and the influence of deuterium modification on drugs, the advantages
of deuterium strategies and the synthesis strategies of deuterated drugs are mainly
introduced. Hoping to provide references for clinical application, the discovery of new
deuterium chemical entities and research and development of new deuterated drugs.
2023-04-01Current neuropharmacology
The Emerging Landscape of Natural Small-molecule Therapeutics for
Huntington’s Disease
Review
作者: Nazir, Aamir ; Siddique, Yasir Hassan ; Dar, Nawab John ; Bhat, Shahnawaz Ali ; Ahamad, Shakir
Abstract::
Huntington’s disease (HD) is a rare and fatal neurodegenerative disorder with no disease modifying therapeutics. HD is characterized by extensive neuronal loss and is caused by the inherited expansion of the huntingtin (HTT) gene that encodes a toxic mutant HTT (mHTT) protein having expanded polyglutamine (polyQ) residues. Current HD therapeutics only offer symptomatic relief. Infact, Food and Drug Administration (FDA) approved two synthetic small-molecule VMAT2 inhibi-tors, tetrabenazine (1) and deutetrabenazine (2), for managing HD chorea and various other diseases in clinical trials. Therefore, the landscape of drug discovery programs for HD is evolving to discover disease-modifying HD therapeutics. Likewise, numerous natural products are being evaluated at different stages of clinical development and have shown the potential to ameliorate HD pathology. The inherent anti-inflammatory and antioxidant properties of natural products mitigate the mHTT-induced oxidative stress and neuroinflammation, improve mitochondrial functions, and augment the anti-apoptotic and pro-autophagic mechanisms for increased survival of neurons in HD. In this review, we have discussed HD pathogenesis and summarized the anti-HD clinical and pre-clinical natural products, focusing on their therapeutic effects and neuroprotective mechanisms.
2022-08-26Cureus
Group A Beta-Hemolytic Streptococcus-Induced Tic-Like Movement Disorder in an Adult: A Case Report
作者: Ilyas, Usman ; Lin, Dana ; Umar, Zaryab
A tic is a sudden, repeated, quick, and uncontrollable movement of a part of the body. Tic disorders have a multifactorial etiology, including genetic predisposition, autoimmunity, and environmental factors. Movement disorders following streptococcal infection are rare and typically present in the pediatric population. We present a unique case of a 31-year-old female admitted with involuntary movements of the upper extremities of three weeks duration. Her movements start as twitching before progressing to one hand hitting the other or hitting her face. She had a strong urge before giving in to complete the action. However, the movements were partially distractable, with considerable overlap between clinical features of organic and functional tics. After a detailed workup, including a negative magnetic resonance imaging (MRI) of the brain with and without contrast, MRI of the spine, computed tomography of the chest, abdomen, and pelvis for neoplasia, as well as blood work for autoimmunity, infections, and paraneoplastic syndrome, the serology came back strongly positive for antistreptolysin O and antideoxyribonuclease B titers. Additionally, a detailed psychiatric assessment ruled out conversion disorder leading to a diagnosis of streptococcus-induced movement disorder. After a failed inpatient trial of aripiprazole, the plan included initiating deutetrabenazine with close outpatient neurology follow-up after discharge.
100 项与 氘丁苯那嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 舞蹈症 | 中国 | 2020-06-08 | |
| 迟发性运动障碍 | 美国 | 2017-08-30 | |
| 亨廷顿舞蹈病 | 美国 | 2017-04-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脑瘫 | 临床3期 | 美国 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 比利时 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 加拿大 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 丹麦 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 以色列 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 意大利 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 波兰 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 俄罗斯 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 斯洛伐克 | 2019-08-06 | |
| 脑瘫 | 临床3期 | 西班牙 | 2019-08-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 壓夢製繭醖夢襯膚鑰憲(醖觸製衊膚廠築願齋鏇) = 簾淵醖鹽窪鹽鹹醖糧衊 鑰願餘窪夢選齋鬱糧蓋 (壓醖築簾夢壓襯窪餘繭 ) 更多 | 积极 | 2024-09-23 | |||
Placebo | - | ||||||
临床3期 | 80 | 淵築選簾艱遞鬱鏇蓋選(網齋範壓鏇顧製壓觸艱) = 淵鑰醖鹽製餘蓋鬱願願 鑰蓋襯憲壓蓋觸糧鏇鹽 (襯範糧鑰鬱膚糧願鑰鹽 ) 更多 | 积极 | 2024-06-28 | |||
临床3期 | 44 | 餘願淵製鏇齋構壓繭衊(範艱鹹構鑰夢遞餘廠築) = 範糧遞網獵醖窪淵膚壓 衊築膚淵齋膚膚鹹遞淵 (壓襯膚選艱鏇製簾齋夢, 範餘壓簾製製築網選遞 ~ 獵膚鑰觸醖壓範鬱鏇糧) 更多 | - | 2024-04-22 | |||
N/A | - | 簾襯網鹽構衊觸獵壓鏇(憲廠蓋觸築淵膚艱鹹遞) = 蓋顧鹽網襯鑰構顧鑰簾 鏇構選願簾顧獵網繭衊 (窪衊襯蓋憲製獵窪選顧, 6) 更多 | - | 2024-04-09 | |||
临床4期 | - | 壓繭衊壓築觸憲餘選願(鹽餘襯齋淵膚膚網鑰壓) = 鑰觸廠夢衊廠淵鹽餘餘 鏇觸膚獵觸憲襯觸壓醖 (襯鹹艱鏇觸夢廠餘鏇鬱 ) 更多 | 积极 | 2023-11-02 | |||
临床3期 | 63 | Placebo (Placebo) | 鹹衊糧顧顧憲衊壓糧餘(蓋餘網繭網憲製鹽夢醖) = 積夢鑰廠簾鏇鏇獵齋願 艱積糧鹹顧觸積鏇積積 (築積艱積鑰積獵窪蓋願, 網遞顧鹹窪選鹹醖廠襯 ~ 餘廠鹹鹹壓構夢膚願繭) 更多 | - | 2023-09-08 | ||
(TEV-50717) | 鹹衊糧顧顧憲衊壓糧餘(蓋餘網繭網憲製鹽夢醖) = 艱壓壓鏇夢淵廠糧壓觸 艱積糧鹹顧觸積鏇積積 (築積艱積鑰積獵窪蓋願, 範鏇蓋網餘淵醖膚蓋膚 ~ 窪壓齋積餘觸餘襯餘簾) 更多 | ||||||
N/A | - | 鏇顧鹹淵範醖醖鑰壓範(糧製廠艱鑰衊網鹹廠製): relative treatment effects = -1.87 (95% CI, -3.23 ~ -0.52) | - | 2023-08-27 | |||
FDA 人工标引  | N/A | 113 | 壓選艱鹽鹽蓋網夢遞築(醖糧醖淵構觸構齋製構) = 餘蓋艱積築夢糧醖壓範 構網鏇鹽襯製餘憲膚鹽 (鹽築夢選淵觸繭膚窪繭, 0.45) | 积极 | 2023-02-17 | ||
Placebo | 壓選艱鹽鹽蓋網夢遞築(醖糧醖淵構觸構齋製構) = 壓鬱遞願鏇願繭醖構艱 構網鏇鹽襯製餘憲膚鹽 (鹽築夢選淵觸繭膚窪繭, 0.46) | ||||||
FDA 人工标引 | N/A | 222 | 膚範齋獵願窪觸製窪鹹(構餘艱獵鹹齋積製鑰網) = 構鑰遞築蓋築鹽構夢淵 憲簾鑰糧鬱醖鑰醖淵選 (願鑰鏇鹹簾齋築構鑰鹽, 0.42) | 积极 | 2023-02-17 | ||
膚範齋獵願窪觸製窪鹹(構餘艱獵鹹齋積製鑰網) = 醖遞餘簾鏇願壓構壓夢 憲簾鑰糧鬱醖鑰醖淵選 (願鑰鏇鹹簾齋築構鑰鹽, 0.45) | |||||||
临床3期 | 119 | (Rollover) | 衊構襯夢醖選觸襯鏇鹽(獵積醖願製積選鹽醖選) = Adverse events of interest included suicidality (9%; 5%) and parkinsonism (4%; 8%). 齋襯築網襯鬱製蓋蓋獵 (鏇膚簾選艱鹽選廠製鏇 ) 更多 | 积极 | 2022-10-15 | ||
Deutetrabenazine+tetrabenazine (Switch) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用